Long noncoding RNA HULC promotes colorectal carcinoma progression through epigenetically repressing NKD2 expression

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Long noncoding RNAs (lncRNAs) are increasingly recognized as key regulators in human diseases, including cancer.
• While HULC is implicated in gastric and liver cancers, its role in colorectal carcinoma (CRC) remains unclear.

Purpose of the Study:

• To investigate the expression, function, and mechanism of lncRNA HULC in colorectal cancer.
• To determine if HULC acts as an oncogene in CRC tumorigenesis.

Main Methods:

• Quantitative real-time PCR to assess HULC expression.
• In vitro assays (proliferation, migration, invasion, apoptosis) and in vivo xenograft models to evaluate HULC function.
• RNA immunoprecipitation (RIP) and RNA pull-down assays to identify molecular interactions.

Main Results:

• HULC is over-expressed in CRC tissues and associated with poor prognosis and shorter survival.
• Knockdown of HULC inhibits CRC cell proliferation, migration, invasion, and tumorigenicity, while promoting apoptosis.
• HULC interacts with EZH2 to repress NKD2 transcription, and this repression is crucial for HULC's oncogenic function.

Conclusions:

• HULC is an oncogenetic lncRNA that promotes colorectal tumorigenesis.
• HULC's mechanism involves the repression of NKD2 via interaction with EZH2.
• HULC represents a potential therapeutic target for colorectal cancer.